RE: The trial they should have done... Bail...The upshot of this is that not a penny of Urocidin value was baked in to the share price of Bioniche, even after the impressive P3A results were made public. I have always found that to be an inverse accomplishment that few, if any corporations, could muster on their worst day. That "no value for Human Health" concept is not my assessment but the assement of Ms McIver, our only real analyst. I believe that it was noted laast month in the 55 cent range.
That inexplicable inability to drive even a nickel of value for the asset couldn't prevent us from dropping 20% today though. How is it possible that the asset is deemed by the market to be worth nothing, yet when the asset is allegedly diminished it shaves 20% off the share price? Only at BNC.
On another note, has anyone ever said that the US was the only market open to a new bladder cancer therapy. I have heard Canada mentioned a few times on and off the record.